Liraglutide is a synthetic GLP-1 receptor agonist used to treat type 2 diabetes, obesity, and in some cases, to reduce cardiovascular risk. It works by mimicking the hormone GLP-1 (glucagon-like peptide-1), which helps regulate blood sugar, slows gastric emptying, and reduces appetite.

Marketed under brand names like Victoza (for diabetes) and Saxenda (for weight loss), liraglutide is administered via daily subcutaneous injection. It is FDA-approved and widely prescribed for blood glucose control and long-term weight management.